Snowden Capital Advisors LLC Gilead Sciences, Inc. Transaction History

Snowden Capital Advisors LLC

$3.29 Billion
Q3 2024

A detailed history of Snowden Capital Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Snowden Capital Advisors LLC holds 67,143 shares of GILD stock, worth $6.03 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

67,143

Previous 107,945 37.8%

Holding current value

$6.03 Million

Previous $7.41 Million 24.02%

% of portfolio

0.17%

Previous 0.22%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$66.59 - $83.99 $2.72 Million - $3.43 Million	-40,802 Reduced 37.8%	67,143 $5.63 Million
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $796,637 - $919,381	12,615 Added 13.23%	107,945 $7.41 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $757,459 - $923,702	10,582 Added 12.49%	95,330 $6.98 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $18,097 - $20,523	247 Added 0.29%	84,748 $6.87 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $349,144 - $380,923	-4,722 Reduced 5.29%	84,501 $6.33 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $90,147 - $102,826	-1,186 Reduced 1.31%	89,223 $6.88 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $572,480 - $652,232	-7,405 Reduced 7.57%	90,409 $7.5 Million
Q4 2022 Feb 13, 2023	SELL	$62.32 - $89.47 $86,437 - $124,094	-1,387 Reduced 1.4%	97,814 $8.4 Million
Q3 2022 Nov 09, 2022	BUY	$59.54 - $68.01 $21,851 - $24,959	367 Added 0.37%	99,201 $6.12 Million
Q2 2022 Aug 12, 2022	BUY	$57.72 - $65.01 $262,683 - $295,860	4,551 Added 4.83%	98,834 $6.11 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $896,543 - $1.12 Million	15,479 Added 19.64%	94,283 $5.61 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $5.11 Million - $5.8 Million	78,804 New	78,804 $5.72 Million
Q3 2021 Feb 05, 2024	SELL	$67.69 - $73.03 $4.98 Million - $5.37 Million	-73,531 Reduced 87.02%	10,970 $766 Million
Q2 2021 Jan 08, 2024	BUY	$63.47 - $69.35 $331,757 - $362,492	5,227 Added 95.02%	10,728 $739 Million
Q1 2021 Jan 08, 2024	BUY	$60.0 - $68.46 $78,120 - $89,134	1,302 Added 31.01%	5,501 $356 Million
Q4 2020 Jan 08, 2024	SELL	$56.65 - $64.55 $396,153 - $451,398	-6,993 Reduced 62.48%	4,199 $245 Million
Q3 2020 Jan 08, 2024	BUY	$62.1 - $78.08 $70,856 - $89,089	1,141 Added 11.35%	11,192 $707 Million
Q2 2020 Jan 08, 2024	BUY	$72.34 - $84.0 $336,308 - $390,516	4,649 Added 86.06%	10,051 $773 Million
Q1 2020 Jan 08, 2024	BUY	$62.63 - $80.22 $62,630 - $80,220	1,000 Added 22.72%	5,402 $404 Million
Q4 2019 Jan 30, 2024	BUY	$61.62 - $67.78 $5,730 - $6,303	93 Added 2.16%	4,402 $286 Million
Q4 2019 Jan 08, 2024	BUY	$61.62 - $67.78 $5,730 - $6,303	93 Added 2.16%	4,402 $286 Million
Q3 2019 Jan 30, 2024	SELL	$62.51 - $69.0 $2,437 - $2,691	-39 Reduced 0.9%	4,309 $273 Million
Q3 2019 Jan 08, 2024	SELL	$62.51 - $69.0 $1.42 Million - $1.56 Million	-22,654 Reduced 84.02%	4,309 $273 Million
Q2 2019 Jan 30, 2024	SELL	$61.87 - $69.38 $4.96 Million - $5.56 Million	-80,153 Reduced 94.85%	4,348 $294 Million
Q2 2019 Jan 08, 2024	BUY	$61.87 - $69.38 $1.39 Million - $1.55 Million	22,404 Added 491.42%	26,963 $294 Million
Q1 2019 Jan 08, 2024	SELL	$62.53 - $70.05 $22,260 - $24,937	-356 Reduced 7.24%	4,559 $296 Million
Q4 2018 Jan 08, 2024	BUY	$60.54 - $79.0 $847 - $1,106	14 Added 0.29%	4,915 $307 Million
Q3 2018 Jan 08, 2024	BUY	$71.28 - $78.92 $349,343 - $386,786	4,901 New	4,901 $378 Million
Q3 2016 Jan 08, 2024	SELL	N/A	-11,511 Closed	0 $0
Q2 2016 Jan 08, 2024	SELL	N/A	-11,238 Reduced 49.4%	11,511 $960 Million
Q1 2016 Jan 08, 2024	SELL	N/A	-61,752	22,749 $2.09 Billion

Others Institutions Holding GILD

# of Institutions

1,931

Shares Held

991M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Snowden Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Snowden Capital Advisors LLC with notifications on news.

Account

Snowden Capital Advisors LLC Gilead Sciences, Inc. Transaction History